Posted by Michael Wonder on 30 Aug 2016
CADTH recommends the reimbursement of Invokamet (canagliflozin hemihydrate with metformin hydrochloride)
25 August 2016 - CADTH has published its final recommendation on the reimbursement of Invokamet in Canada.
The CADTH Canadian Drug Expert Committee had recommended that canagliflozin hemihydrate with metformin hydrochloride be reimbursed for patients with type 2 diabetes mellitus who are already stabilized on therapy with canagliflozin hemihydrate and metformin hydrochloride, to replace the individual components of canagliflozin hemihydrate and metformin hydrochloride, who have inadequate glycemic control on metformin hydrochloride and a sulphonylurea, and for whom insulin is not an option.
The drug plan costs for the canagliflozin hemihydrate metformin hydrochloride fixed-dose combination should not exceed the combined cost of canagliflozin hemihydrate and metformin hydrochloride administered separately.
